Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
Condition(s):Refractory Solid TumorLast Updated:July 27, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Refractory Solid TumorLast Updated:July 27, 2023Recruiting
Condition(s):Prostate Cancer; Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate CancerLast Updated:March 12, 2024Not yet recruiting
Condition(s):Refractory Thyroid Gland Carcinoma; Refractory Thyroid Gland Papillary Carcinoma; Refractory Thyroid Gland Follicular Carcinoma; Refractory Thyroid Gland Hurthle Cell CarcinomaLast Updated:July 11, 2023Recruiting
Condition(s):Prostate Cancer Metastatic; Castration Resistant Prostatic Cancer; Advanced Prostate CarcinomaLast Updated:December 8, 2022Recruiting
Condition(s):Pancreatic Ductal Adenocarcinoma; Gastroesophageal Adenocarcinoma; Glioblastoma MultiformeLast Updated:February 9, 2024Recruiting
Condition(s):Metastasis From Malignant Tumor of ProstateLast Updated:February 29, 2024Active, not recruiting
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:August 28, 2023Completed
Condition(s):Metastatic Prostate CancerLast Updated:September 22, 2023Recruiting
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:November 14, 2022Recruiting
Condition(s):Prostate NeoplasmLast Updated:November 14, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.